Skip to main content

News

29 Jan, 2016 EMPOWER Program Receives 16 Letters of Intent
Collaboration Advances Preeclampsia Research in Low- and Middle-Income Countries The EMPOWER Program has received 16 Letters of Intent in response to its request for research proposals related to pre-eclampsia and other hypertensive disorders of pregnancy from young investigators in low resource settings. Of the 16 proposals, six project that were deemed feasible  have... Read More
29 Jan, 2016 Global Pregnancy Collaboration (CoLab): Updates (December-January 2016)
Since September, CoLab members have been working to follow up on the ideas developed in response to presentations at our annual meeting in Oxford. The working groups envisioned at the meeting have been formed, and they have begun to move toward possible funding strategies to explore these new ideas. One group plans to determine the cardiovascular risk factors prior to... Read More
29 Jan, 2016 Objective 3: GHP Trial Updates (December - January 2016)
GHP Trial enrollment graph as of December 2015. The GHP Oral Antihypertensive Trial aims to compare the efficacy of oral labetalol, oral nifedipine, and oral methyldopa for the management of severe hypertension in pregnant women. The study is enrolling in two sites in Nagpur, India: Government Medical College (GMC) and Daga Women’s Hospital. The GHP Trial has enrolled... Read More
29 Jan, 2016 Objective 1: CAP Study Update (December-January 2016)
CAP enrolment graph (July 2011 - December 2015) The CAP Study Women with a history of pre-eclampsia in their most recent pregnancy who agree to participate receive calcium 500mg daily or placebo from enrolment until they become pregnant, and up to 20 weeks of pregnancy. The primary outcome is pre-eclampsia. CAP study progress As evident from the recruitment graph... Read More
30 Nov, 2015 PRE-EMPT Fifth Annual Meeting
PRE-EMPT hosted its Fifth Annual Meeting in North Vancouver at Pinnacle at the Pier Hotel on October 2nd, 2015. There were one hundred attendees, which comprised of local and international researchers, clinicians, academics, government stakeholders, and non-governmental organisations including the World Health Organization, and Jhpiego. Attendees came from Canada, United... Read More
30 Nov, 2015 PRE-EMPT at the XXI FIGO Congress
On October 4, 2015, PRE-EMPT hosted a pre-congress course, PRE-EMPT Global Symposium on the Hypertensive Disorders of Pregnancy, at the XXI FIGO Congress in Vancouver, Canada. Our symposium was truly global, as we had international experts in maternal health research from countries such as Argentina, Australia, India, and South Africa who spoke at our symposium. The main... Read More
30 Nov, 2015 2015 Vision Grants for Pre-eclampsia Research Announced
The Preeclampsia Foundation has announced that Shannon Bainbridge, PhD, and Richard Burwick, MD, are the recipients of its 2015 Vision Grants. These two $20,000 research grants were presented on October 17th at the 2015 North American Society for the Study of Hypertension in Pregnancy (NASSHP) conference held in Chicago, Illinois. Visions grants are awarded to the... Read More
30 Nov, 2015 Objective 3: GHP Trial Updates (August - November 2015)
GHP Trial enrolment graph as of November, 2015. As of November 2015, the GHP Oral Antihypertensive Trial has enrolled 207 women, which is right on target for their enrollment numbers. Congratulations to all of the sites!
23 Nov, 2015 Objective 3: CLIP Trial Updates (August-November 2015)
The Definitive Trial is ongoing in all CLIP sites. As of November 6 2015, 60,933 women have been recruited. The momentum of activity in all the sites bears witness to the continuous hard work put in by the country teams, including the engagement of stakeholders at the household, community and health system level.    A milestone event in October was the formal... Read More
16 Nov, 2015 Objective 1: CAP Study Update (August-November 2015)
CAP enrolment as at 31 October 2015 The CAP Study Women with a history of pre-eclampsia in their most recent pregnancy who agree to participate receive calcium 500mg daily or placebo from enrolment until they become pregnant, and up to 20 weeks of pregnancy. The primary outcome is pre-eclampsia. CAP study progress By 31 October we had recruited 1198 women with 477... Read More

Pages